Loading market dashboard
ProMIS Neurosciences, Inc.
PMNHealthcareNASDAQCA
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
BRISBANE, AUS, June 2, 2026 - (ACN Newswire) - Graphene Manufacturing Group Ltd (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to announce that
Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that it has entered into an exclusive licensing and collaboration agreement with Everest Medicines f
CAMBRIDGE, Mass. , May 28, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming June 2026 conferences, and will be available for one-on-one meetings.
CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming June 2026 conferences, and will be available for one-on-one meetings.
Company closed PIPE financing with gross proceeds of up to $175 million, including the possible exercise of warrants, from long-term global investors. Proceeds are expected to fund the Company through 2027, including completion of the ongoing Phase 1b clinical trial in Alzheimer's disease (AD).
Cambridge, Massachusetts, May 12, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced its financial results for the quarter ended March 31, 2026, and provided a corporate update.
Cambridge, Massachusetts--(Newsfile Corp. - April 13, 2026) - ProMIS Neurosciences, Inc. (NASDAQ: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) and other neurodegenerative disorders, today announced that Neil Warma, Chief Executive Officer, will participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference. The conference is being held April 21-22, 2026, at the Metro Toronto Convention Centre in Toronto, Ontario.
PRECISE-AD Phase 1b trial fully enrolled. Completion of six-month assessments expected in Q2 2026 with blinded interim analysis anticipated early Q3 2026; twelve-month top-line data anticipated in early 2027 PMN310 continues to demonstrate a favorable safety profile, with no treatment-related serious adverse events reported to date Cambridge, Massachusetts,, March 25, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), today announced its financial results for the year ended December 31, 2025, and provided a corporate update.
Promis Neurosciences (NASDAQ: PMN - Get Free Report) is expected to be releasing its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect Promis Neurosciences to post earnings of ($4.22) per share for the quarter. Investors can find conference call details on the company's upcoming Q4 2025 earning report page for the
Cambridge, Massachusetts, March 18, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) and other neurodegenerative disorders, today announced that it will present two scientific posters at the Alzheimer's & Parkinson's Diseases Conference (AD/PD™ 2026), being held March 17–21, 2026 in Copenhagen, Denmark. The posters will highlight ongoing research related to the Company's proprietary discovery platform and its approach to selectively targeting toxic misfolded proteins in neurodegenerative diseases.
Ally Bridge Group NY LLC increased its position in Promis Neurosciences (NASDAQ: PMN) by 367.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,233,497 shares of the company's stock after buying an additional 4,899,069 shares during the quarter. Promis Neurosciences
